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ESTIMATING THE BURDEN OF COPD:
METHODS AND RESULTS FROM THE
GLOBAL BURDEN OF DISEASE STUDY
Summary
Information about the comparative magnitude of
the burden from various diseases and injuries is a
critical input into building the evidence base for
health policies and programmes. Such informa-
tion should be based on a critical evaluation of all
available epidemiological data using standard
and comparable procedures across diseases and
injuries, including information on the age at
death and the incidence, duration and severity
of cases who do not die prematurely from the
disease. A summary measure, disability-adjusted
life yrs (DALYs), has been developed to simulta-
neously measure the amount of disease burden
due to premature mortality and the amount due
to the nonfatal consequences of disease.
Approximately 2.7 million deaths from chronic
obstructive pulmonary disease (COPD) occurred
in 2000, half of them in the Western Pacific
Region, with the majority of these occurring in
China. About 400,000 deaths occur each year
from COPD in industrialised countries. The
increase in global COPD deaths between 1990
and 2000 (0.5 million) is likely to be partly real,
and partly due to better methods and more
extensive data availability in 2000. The regional
(adult) prevalence in 2000 varied from 0.5% in
parts of Africa to 3–4% in North America.
Introduction
Health systems must increasingly address a
broad spectrum of health issues, ranging from
epidemic outbreaks to advanced therapeutic care.
They must, or should, also support disease
prevention and health-promotion activities.
Recognising that resources for health were
unlikely to grow as quickly as demand, in 1993,
the World Bank proposed a series of intervention
packages for countries at different stages of
development which, if implemented, would
probably lead to the greatest gains in population
health at affordable cost. The evidence for these
recommendations was based on a study of the
global burden of disease from various conditions,
and an assessment of the cost-effectiveness of
known interventions against them.
The Global Burden of Disease (GBD) Study,
commissioned for the Bank Report, was the first
ever comprehensive attempt to simultaneously
assess the burden of premature mortality and
nonfatal illness due to .100 diseases and injuries
worldwide [1]. To assess burden, a summary
measure of population health, DALYs, was used,
with the stream of yrs of life lost (YLL) or yrs
lived with disability (YLD) assessed separately.
Thus, for any disease or injury (i) (e.g. lung
cancer, road traffic accidents, measles), prema-
ture mortality was assessed as the following:
YLL~
X
x
dix
:ex ð1Þ
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where dix are deaths from cause i at age x and ex is the standard
expectation of life lost due to death at age x [1]. To assess YLDs,
the principal disabling sequelae (j) from cause i were first
identified and, for each sequela, age- and sex-specific incidence
(Ij) was estimated, as was average age at onset, duration (D) and
severity (S), on a scale of 0–1 (05perfect health, 15death). The
methods and estimation procedures are described in detail
elsewhere [1]. Thus, the following equation holds:
YLD~
X
x
X
j
Ijx
:Dx
j:Sx
j ð2Þ
Overall disease burden, measured by DALYs, was then
estimated as the sum of the two components:
DALY~YLLzYLD ð3Þ
Internal epidemiological consistency for each condition was
forced through a disease model, which simultaneously
estimated age-specific incidence, case fatality, prevalence,
duration and general background mortality [2].
The base year for the original GBD Study was 1990. The World
Health Organization (WHO) subsequently agreed to prepare a
revised assessment for the year 2000, the GBD 2000 Study.
With the substantial interest in the GBD 1990 Study, there have
been several methodological improvements to the way that
epidemiological estimates are prepared, to the architecture of
DALYs, as well as a very substantial increase in the amount of
epidemiological data available [3]. The current authors
describe the basis for deriving the epidemiological estimates
required to compute DALYs from COPD. The key challenge is
to estimate age- and sex-specific death rates from COPD, by
region (there were eight World Bank regions in the 1990 Study
and 14 WHO epidemiological regions in the 2000 Study
(fig. 1)), as well as incidence, prevalence and other epidemio-
logical parameters by age, sex and region. In this paper, the
current authors’ aim is to describe the methods and summarise
the key findings from the GBD 2000 Study, and to evaluate the
impact of the major methodological advances over the
methods and approaches used in 1990 on the comparability
of findings across the two periods.
Estimating COPD mortality
Each year, ,100 countries worldwide report data from their
vital registration systems on causes of death in their popula-
tions [4]. The quality and coverage of these statistics vary
enormously, yet they are of major relevance for public health.
Vital registration systems that capture all deaths in a
population, and include a medical certificate completed by a
qualified practitioner as to the medical conditions preceding
death, are the ‘‘gold standard’’ for assessing causes of death.
Yet, in many countries, these systems either fail to capture all
deaths, fail to provide a specific clinical diagnosis as to the
underlying cause of death, or provide an incorrect cause. This
is true even for developed countries. Thus, many deaths coded
to heart failure or ventricular dysrythmias, for example, in
countries such as Japan, Spain or France would, in the USA,
UK or Australia, be more likely to be recognised as due to
ischaemic heart disease [1]. The implications of such miscoding
can be substantial. For example, when correction algorithms
for vascular disease miscoding were applied in the 1990 GBD
Study, ischaemic heart disease mortality rates in Japan, France,
Brazil and several other countries were estimated to be
FIGURE 1. The World Health Organization mortality subregions used in the Global Burden of Disease 2000 Study. A: very low child and adult mortality; B: low child and
adult mortality; C: low child mortality and high adult mortality; D: high child and adult mortality; E: high child mortality and very high adult mortality; AFR: Africa; AMR:
Americas; EMR: Eastern Mediterranean; EUR: Europe; SEAR: South-East Asia; WPR: Western Pacific.
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50–200% higher than reported [1]. It is unclear whether there
are similar systematic certification and coding biases across
countries for COPD; however, studies of multiple-cause coding
suggest that there might be [5].
In addition to vital registration, other sources of cause-specific
mortality data for populations were identified and evaluated,
including large-scale epidemiological surveillance systems on
a sample basis in China and Tanzania, and, where available,
community-based epidemiological research studies and dis-
ease registers (e.g. cancer). Since claims about causes of death
are often made by disease-specific groups working in isolation
from others (e.g. HIV, malaria), they are often exaggerated and,
when summed, greatly exceed independent demographic
estimates of total mortality in any given age or sex group.
This is especially true for children and young adults where the
impact of most major communicable diseases and conditions
of poverty is primarily concentrated. As a first step, the
‘‘envelope’’ of mortality by age, sex and region was first
estimated from demographic databases, and the estimates of
cause-specific mortality from the .100 causes examined in
the GBD Study were constrained to sum to this number
of deaths.
For countries with vital registration data, the following
procedure was adopted to estimate cause-specific death rates,
including COPD. 1) Where vital registration was incomplete,
data were first corrected for undercount using standard
demographic methods. 2) Ill-defined causes were redistributed
pro rata across defined causes (i.e. deaths with a specific
International Classification of Diseases (ICD) underlying
cause), and deaths of those aged .5 yrs were distributed
across chronic diseases only. 3) For countries/regions where
cause of death registration was considered reliable, COPD
mortality was estimated directly from the data. For each
remaining region, available epidemiological information and
disease models were used to first estimate broad cause of death
groups, by age and sex (group I: communicable, maternal,
perinatal, nutritional; group II: noncommunicable; group III:
injuries) [6]. For each region, a regional ‘‘template’’ of cause-
specific mortality was first constructed using local epidemio-
logical evidence, including sample registration and disease
registries. This template was then applied to the broad group II
estimates of mortality by age and sex to estimate specific
COPD mortality.
Clearly, the estimation procedure in the absence of good vital
registration is highly uncertain and yields, at best, possibly
plausible estimates of mortality rather than observed numbers
of deaths from COPD. Any systematic biases or miscoding of
COPD inherent in the local epidemiological evidence used to
construct the regional template of proportional mortality
would be reflected in the regional mortality estimates. Using
these methods, COPD was estimated to have been the cause of
,2.75 million deaths in 2000, half of them in the Western
Pacific region, and most of these in China. Another 650,000
COPD deaths were estimated to have occurred in the South-
East Asia region, largely in India (table 1). In the industrialised
countries as a whole (the very low child and adult mortality
(A) regions), COPD caused ,300,000 deaths, or 10% of the
global total. Worldwide, 1.9% of DALYs were attributable to
COPD in 2000; these estimates show some regional variability
according to WHO subregions defined on the basis of
epidemiological and demographic transition (table 1).
The same broad approach to estimating COPD mortality was
adopted in 1990, but with less rigorous methods for estimating
group I/II/III and all-cause mortality, and with less vital
registration data. In that year, 2.2 million deaths were
estimated from COPD, although it is difficult to know whether
the increase over the decade (0.55 million deaths) is real or
largely due to these methodological and data advances.
Certainly, a key driver of global mortality from COPD is
China and, until a competent evaluation of the Chinese Disease
Surveillance Points System is carried out, which is the primary
source of epidemiological data for the country, the regional
and, hence, global estimates of COPD mortality will remain
uncertain [8].
Estimating prevalence
Despite the fact that COPD is now prevalent in both developed
and developing countries, largely as a result of the tobacco
epidemic, reliable estimates of its prevalence are surprisingly
scant in most parts of the world [9–11]. There is now a
consensus that COPD is characterised by airways obstruction
with lung function levels of forced expiratory volume in one
second (FEV1)/forced vital capacity ,70% and presence of a
post-bronchodilator FEV1 ,80% of the predicted value that is
not fully reversible [12, 13]. However, population-based
estimates of COPD prevalence by region are problematic,
TABLE 1 Estimated chronic obstructive pulmonary
disease deaths and disability-adjusted life yrs
(DALYs) by World Health Organization (WHO)
region, 2002
Region Deaths
thousands
DALYs
thousands
% of regional
total DALYs
AFR A 52 514 0.3
AFR E 65 668 0.3
AMR A 141 1743 3.7
AMR B 90 1419 1.7
AMR D 10 195 1.1
SEAR B 100 1420 2.3
SEAR D 556 6740 1.9
EUR A 140 1744 3.4
EUR B 45 673 1.8
EUR C 76 1036 1.7
EMR B 15 349 1.5
EMR D 80 989 0.9
WPR A 21 415 2.5
WPR B 1354 9820 4.0
World 2748 27756 1.9
A: very low child and adult mortality; B: low child and adult mortality; C: low
child mortality and high adult mortality; D: high child and adult mortality; E: high
child mortality and very high adult mortality; AFR: Africa; AMR: Americas; SEAR:
South-East Asia; EUR: Europe; EMR: Eastern Mediterranean; WPR: Western
Pacific. The mortality strata (A–E) were used to distinguish groupings of
countries likely to be at a similar level of health development among the
member states of the WHO regions. Adapted from [7].
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since the disease is progressive, measurement tools and
definitions still vary among studies, and implementation of
spirometry is often not feasible in developing regions [14].
In such circumstances, observed incidence and prevalence
become highly dependent on factors other than the true
occurrence of disease. For example, prevalence based on self-
reported symptoms (chronic cough, sputum, etc.) probably
overestimates true COPD prevalence due to misclassification
of other possible respiratory diseases. Typically, only about
half of the patients with symptoms of chronic bronchitis
actually have COPD as assessed by spirometry (table 2).
Conversely, physician diagnosis usually underestimates true
COPD prevalence. In the USA, for instance, ,60–70% of those
with lower FEV1 have never had a diagnosis of COPD [15].
Furthermore, there is a considerable variation among studies
in terms of case definition, study design, sample size and data
analysis, which makes comparisons among studies difficult.
Even in the industrialised (A) regions, there is little con-
sensus across definitions as to the true prevalence of COPD.
Moreover, since prevalence figures are not available in many
developing regions, an alternative approach is needed. What
the current authors have done is to infer disease occurrence
from mortality figures, with the help of the mathematical
constraints imposed by forcing consistent epidemiological
relationships among prevalence/incidence, remission and
mortality rates [16]. The disease model, DISMOD, is used to
back-calculate consistent estimates of COPD incidence and
prevalence [3]. The main advantage of this approach is that
incidence, prevalence and mortality estimates are iteratively
linked through the causal chain of a disease process, and this
chain limits the possible combinations of incidence, prevalence
and mortality rates [2]. Limits can be imposed, since any
prevalent case must have become incident at a younger age,
and any person who died with a disease must have become
incident previously, and have been prevalent.
Methods
In order to estimate prevalence of COPD in a disease model
linking incidence, prevalence, duration and case fatality, the
relative risk of dying from COPD mortality (or the case-fatality
rate) is required [16–19]. One approach to approximating the
relative risk (RR) of COPD mortality is to use information on
risk factors associated with COPD (i.e. RR5DR1/DR0 where
DR1 and DR0 are death rates in exposed (1) and unexposed (0)
groups). COPD mortality was modelled as a function of risk
factors and other possible determinants, along with regional
fixed effects of the following form:
rij~Mij=PYij~exp(az
X
i
biXizWjREGIONjzeij) ð4Þ
where rij is age- and sex-specific COPD mortality rate, Mij is
number of deaths in each age group, PYij is person-yrs at risk
approximated by mid-yr population by age and sex, Xi is risk
factor variables, and REGIONj is regional fixed effect.
Goodness of fit and deviation of errors were assessed to choose
the best fit regression model. By modelling in this way, the RR
of death from COPD for each region can be approximated by
the relative impact of COPD risk factors. In other words:
RR~DR1=DR0~exp(
X
i
bi(Xi1{Xi0)) ð5Þ
Three major risk factors have been identified for COPD,
namely: 1) cigarette smoking; 2) heavy exposure to occupa-
tional and indoor air pollution; and 3) a1-antitrypsin deficiency
[9, 12, 13, 20]. While cigarette smoking accounts for 80–90% of
COPD risks in developed countries, smoking behaviour alone
is not sufficient to explain the geographical difference in
prevalence rate of symptoms [9, 21]. Studies have suggested
that the prevalence rate for symptoms increases with increas-
ing levels of air pollution, independent of cigarette consump-
tion, indicating that outdoor and indoor air pollution may
account for the geographical differences. Several studies in
developing countries have shown a significant relationship
between female COPD prevalence and the use of biofuels
[22, 23].
Although excess mortality has been noted during periods of
excessive outdoor air pollution in both developed and
developing countries, to date, the role of outdoor air pollution
in the aetiology of COPD remains unclear [9, 24]. WHO’s
Comparative Risk Assessment database provides information
on exposure to both smoking and indoor air pollution by
region [25]. Although data on occupational dust exposure is
not yet widely available, its role is thought to be much smaller
compared with that of cigarette smoking and indoor air
pollution [26]. Finally, severe a1-antitrypsin deficiency is a
recessive trait common in individuals from Northern Europe
and virtually absent from other populations. Prevalence is
estimated to be much less than 1% in the general population
and has thus been excluded from the model.
Other potential factors related to COPD prevalence include
age, sex, race/ethnicity and socio-economic status [12].
Increasing prevalence with advancing age may reflect either
TABLE 2 Estimated differences in chronic obstructive
pulmonary disease regional prevalence
according to definition used for age groups
o30 yrs
Region Prevalence %
Symptoms Physician diagnosis Spirometry
AFR D 1–3
AMR A 5–15 1–3 2–5
AMR B 5–13
EMR B 2–10 1–2
EUR A 10–20 2–5 3–7
EUR B 10–20
SEAR D 2–7
WPR A 10–15 2–5
WPR B 2–8 1–3
Regions without prevalence studies have been omitted. A: very low child and
adult mortality; B: low child and adult mortality; D: high child and adult mortality;
AFR: Africa; AMR: Americas; EMR: Eastern Mediterranean; EUR: Europe;
SEAR: South-East Asia; WPR: Western Pacific. See Supplementary material on
website for information regarding the source of these data.
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cumulative exposure to smoking and other risk factors, loss of
elasticity of lung tissue or both. To take this factor into account,
the current model incorporates age as an independent variable.
In general, COPD is more prevalent in males, reflecting
differential exposure to risk factors. However, a higher
COPD prevalence has been observed among females in the
South-East Asia region than males due to indoor air pollution
[22, 27]. Sex has been included as a variable in the model to
adjust for the sex differential in risk exposure and possibly in
susceptibility, since the data on biofuel use is only available as
a proportion of the population exposed. It has also been
suggested that higher COPD prevalence is observed among
certain races and ethnic groups, but this is most likely due to
confounding by differences in exposure to risk factors, access
to healthcare, etc.
The final regression model used in the GBD 2000 Study was as
follows:
rijk~Mijk=PYijk~exp(azb1SIRijkzb2AIRijk
zliSEXizdjAGEjzwkREGIONkzeijk)
ð6Þ
where SIR is the smoking impact ratio that approximates
cumulative past exposure to smoking [21], AIR is a proportion
of households using biofuel, and SEX and AGE are dummy
variables for sex and age, respectively.
From this regression model, the relative risk of COPD-related
mortality can be approximated by:
RR~DR1=DR0~exp(b1(SIR1{SIR0)zb2(AIR1{AIR0)) ð7Þ
where SIR0 and AIR0 are set to zero in the unexposed groups.
A further advantage of this approach is that it yields an
independent estimate of age- and sex-specific regional mor-
tality from COPD, derived using a quite different (regression-
based) approach to that described earlier. The results of the
two approaches are compared in the following section.
Disability weights
Some estimate of the severity of COPD in patients is required
in order to determine disability weights and, hence, YLDs from
the disease. The traditional approach to caring for COPD
patients has been to rely on pulmonary function testing to
quantify severity, and to assess response to therapy. However,
patients with COPD seek medical care because of symptoms,
in particular dyspnoea and inability to function, which clearly
have an impact on an individual’s health-related quality of life
(HRQoL). Accordingly, instruments have been developed to
provide a standardised method to measure health status and
levels of disability [28].
It has been suggested that when the FEV1 falls to ,50% of that
predicted for a healthy population, the individual typically
first experiences some activity limitation because of dyspnoea.
When FEV1 reaches a level of 30–40% of that predicted, there
would be significant exercise limitations, which can be
severely disabling [29, 30].
For the GBD 2000 Study, disability weights rather than disease-
specific HRQoL scores have been employed. The original
disability weights for untreated and treated COPD in the GBD
1990 Study were 0.428 and 0.388, respectively [1]. Recent
national burden of disease studies in Australia and the USA
used an aggregated disability weight based on the Dutch
disability weight exercise in which mild/moderate and severe
COPD were assigned the weights of 0.17 and 0.53, respectively.
For the GBD 2000 Study, it was decided that disability weights
from these national burden of disease studies should be
employed. For the purpose of comparison, YLDs based on
current incidence estimates and the GBD 1990 Study disability
weights were also calculated.
It has been suggested that treatment can improve the quality of
life among COPD patients, but only smoking cessation can
alter prognosis and progression [10, 31]. Hence, the majority of
current treatments for COPD are conservative, but some
improvement in the HRQoL score has been observed (for
example, for a bronchodilator [32], for lung rehabilitation [33,
34], for treatment guidelines [35], for lung volume-reduction
surgery [36]). Changes in a generic HRQoL instrument (i.e. the
Short Form-36) score ranged from 14% (rehabilitation) to 22%
(volume-reduction surgery). Hence, for the assessment of the
treatment effect, a conservative 14% reduction in the disability
weight as a treatment effect was employed, which is slightly
larger than that used in the GBD 1990 Study.
Results
The final regression model (equation 6) achieved a consider-
ably high goodness of fit, with no systematic deviation among
residuals. The coefficients for smoking (i.e. SIR) and biofuel use
were both positive (1.111 and 2.108, respectively) and highly
significant. As expected, the coefficients describing the effect
of age on COPD mortality rose monotonically with age
(1.664, 3.694, 5.662, 6.922, 8.068 for the age groups 30–44, 45–
59, 60–69, 70–79 and o80 yrs, respectively). Overall, the model
accounted for much of the variation in estimated COPD
mortality among regions, with an R250.942.
Predicted mortality was consistent with the GBD 2000
mortality estimates, except for males in South-East Asia
(SEAR) with high child and adult mortality (D) where the
GBD 2000 Study estimates were lower than predicted. This
may well be due to problems with the regional cause of death
template, and more confidence should be placed in the model-
based predictions.
This model was used to estimate age- and sex-specific RRs of
COPD-related mortality by region. For the purpose of
comparison, the RRs used in the GBD 1990 Study, current
model estimates, and the recent USA national burden of
disease study (unpublished data) are shown in figure 2. The
patterns of age- and sex-specific RRs are consistent among
studies except for the GBD 1990 estimates, which highlight the
limitations of the constant survival values approach used in
that study.
Figure 3 shows estimated age-specific incidence and preva-
lence per 100,000, by broad regions in 2000, using these
methods. Incidence rates rise with age, as expected, and are
higher for males than females in all regions. By far the highest
incidence is estimated for the Western Pacific (WPR) low child
and adult mortality (B) region (primarily China) with rates at
age o60 yrs of 2–3 times those of other regions. Age-specific
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prevalence of the disease is also highest in WPR B in most
cases, but, interestingly, is also high in Latin America (AMR) B
and D, and A regions. Prevalence rates in these regions are 3–4
times those for other parts of the world.
Table 3 shows the summary estimates of adult (aged o30 yrs)
prevalence of COPD, by region, for 2000. Table 3 also provides
a comparison of prevalence estimates from the 1990 GBD
Study, with the range of published (as of 2002) estimates in the
literature. In general, the current (i.e. 2000) model estimates
were more consistent with the results of the published
literature than the 1990 estimates. In particular, the previous
estimates highly underestimated COPD prevalence in AMR A,
Europe (EUR) A and WPR A (i.e. the industrialised countries),
where the prevalence of smoking was higher than in other
regions. Conversely, the current estimates yielded lower
prevalence rates in Africa (AFR).
Based on the estimated age-specific mortality, and the
incidence/duration and severity weights from these methods,
disease burden from COPD was calculated by region for 2000.
These estimates are shown in table 4.
Overall, COPD was estimated to have caused .26 million
DALYs in 2000, or just ,2% of the global total. Of this, WPR B
(including China) and SEAR D (including India) accounted for
36% and 25%, respectively. Despite a lower prevalence in these
regions than in other regions where risk factors are more
prevalent, the large population in both regions contributed to
the larger total morbidity from COPD. They were followed by
smoking-prevalent regions, such as EUR A (6.7%) and AMR A
(6.0%). The male/female ratios of total YLDs and YLLs were
1.4 and 1.1, respectively. The ratios tended to be higher in AFR,
EMR and WPR B regions where smoking prevalence among
females is still low. Overall, YLDs accounted for 38% of the
total COPD burden, but YLDs exceeded YLLs in some
mortality subregions (A and B).
Figure 4 shows a comparison of YLDs per 100,000 population
by region in GBD 1990 and GBD 2000. Total burden of COPD
was larger in the GBD 1990 estimate than the present estimate
partly because GBD 1990 tended to overestimate COPD
incidence in regions such as AFR and WPR B, and partly
because GBD 1990 employed higher severity weights across
the regions. It should be noted, however, that actual
epidemiological parameters such as mortality and prevalence
rates increased considerably in 2000.
Discussion and conclusions
In the current paper, an alternative approach to estimating
COPD incidence and prevalence has been described, which
was used for estimating YLDs due to COPD in 2000.
Compared with the previous estimates in GBD 1990, which
employed uniform RRs across the regions, the revised method
has the advantage of including regional variations in RRs of
COPD-related mortality [1]. However, several limitations
should be noted.
First, estimated RRs are not the true RRs of COPD-related
mortality; rather they are approximated by the two major risk
factors for COPD, i.e. RRs of joint effects of smoking and air
pollution. Conversely, since the goodness of fit of the
regression model was high (0.942), COPD-related mortality
would be well represented by the risk factor analysis.
Estimated prevalence rates were comparable to those pub-
lished in the literature, ensuring the validity of the present
approach. However, it is likely that the current GBD Study
underestimates the true prevalence of COPD. At the time of
analysis (2002), ,30 studies of COPD prevalence were
available to prepare regional estimates. More recent reviews
[37, 38] have identified newer published studies from which
updated prevalence estimates can be made. These data will
be taken into account in any subsequent revision of the
GBD Study.
Secondly, COPD mortality estimated for GBD 2000 may be still
be an underestimate. A recent study in Canada by LACASSE et al.
[33] has suggested that COPD mortality was much lower than
that estimated by MANNINO et al. [5] from the USA multiple
causes of death data. In fact, the study by MANNINO et al. [5]
suggested that mortality from COPD was highly under-
estimated when using vital statistics rather than multiple
causes of death data. However, if asthma was excluded as a
cause of COPD death and cause of death was restricted to the
primary cause, actual mortality figures in Canada and the USA
were comparable, since COPD often coexists with lung cancer
and COPD may often be the secondary cause of death rather
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FIGURE 2. Comparison of relative risks of chronic obstructive pulmonary
disease-related mortality by age and sex for a) males and b) females.
m: USA burden of disease study; $: Global Burden of Disease Study; &: model
estimates.
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than the primary cause [13]. Therefore, if the data on cause of
death is restricted to the primary cause classified by ICD 9th or
10th revision as in the GBD exercise, COPD mortality is at least
comparable across the regions. The possibility of the miscoding
in COPD is still likely to be smaller than other causes of death.
Nevertheless, the current estimate of COPD burden should be
considered as a lower bound of true COPD burden.
Thirdly, another problem of underestimated mortality would
be overestimation of prevalence, particularly in SEAR D and
EUR B. Since a patient with a disease is selectively being
removed from the population, its prevalence is lower than it
would have been if the disease ran no excess mortality risk [16].
Finally, the main results from this study are estimates of COPD
prevalence rates, which are consistent with a corresponding set
of prevalence and mortality rates and, more importantly,
appear to be more comparable with those in national burden of
disease studies and the published literature than the previous
(1990) estimates. Despite the uncertainty in estimates due to
data limitations, the GBD Study suggests that COPD is a major
cause of death and disability in all regions. More than 2.5
million people die of the disease each year, or about the same
number as HIV/AIDS, and most of these deaths are in poor
countries. COPD is currently the 10th leading cause of disease
burden (DALYs) in the world, causing,2% of the entire global
burden of disease, and this can be expected to rise unless
urgent action is taken to control leading risk factors,
particularly tobacco.
PROJECTING THE FUTURE BURDEN OF COPD
Summary
Methods to project future burden of disease include risk factor
models and extrapolation of past trends. Risk factor models are
intuitively appealing, but complex to construct and require
detailed information on risk factors. Age–period–cohort extra-
polation methods are appropriate for COPD as demographic
changes, lifetime smoking habits (cohort effects) and other
factors may strongly influence future COPD risk. Data
(especially mortality) are often readily available and extra-
polation methods are simple to implement, but can be
difficult to interpret and are probably best for short-term
projections.
To illustrate some of the issues with projecting burden of
disease, a Bayesian age–period–cohort method was used to
project COPD mortality for 2000–2009 in England and Wales
(UK), using routinely available mortality and population data
for 1945–1999.
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FIGURE 3. Estimated age-specific incidence for a) males and b) females, and age-specific prevalence for c) males and d) females of chronic obstructive pulmonary
disease (COPD) by region, 2000. m: industrialised regions with very low child and adult mortality; ¤: Americas, combining the regions with low child and adult mortality, and
high child and adult mortality; &: Europe, combining the regions with low child and adult mortality, and low child mortality and high adult mortality; #: Eastern Mediterranean;
h: South-East Asia; $: Western Pacific regions with low child and adult mortality; e: Africa.
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Testing the model by making predictions for the last 10 yrs of
existing data gave median totals for COPD deaths within 9%
for males and 5% for females. Projections for 2000–2009
suggested a median fall in death rates for males of 24% (90%
credible intervals -52–14%) by 2009 on a 1999 baseline and
corresponding 2% (90% credible intervals -40–65%) rise for
females. The wide credible intervals reflect marked year-to-
year variations in numbers of deaths, probably related to
infectious disease activity.
Credible or confidence intervals are not routinely presented
in current published COPD projections using risk factor
models, but may give useful information. As no method is
perfect, a more complete assessment would compare projections
obtained using risk factor and extrapolation methods.
Introduction
In words attributed to Niels Bohr (1885–1962), ‘‘prediction is
very difficult, especially about the future’’. However, some
TABLE 3 Comparison of chronic obstructive pulmonary disease prevalence for those aged o30 yrs by region, 1990 and 2000
Region Current 2000 estimates % Estimates based on GBD 1990 data % Published prevalence based
on spirometry %
Males Females Males Females Males Females
AFR D 1.1 0.5 2.4 1.4 ,1.0
AFR E 0.6 0.2 2.1 1.3
AMR A 4.0 3.2 1.4 0.7 3.0–5.0 2.0–4.0
AMR B 3.4 2.5 1.5 0.8 2.0–4.0
AMR D 0.7 0.3 1.4 0.7
EMR B 2.3 0.5 0.9 0.9 1.0–2.0 1.0
EMR D 1.8 1.0 0.9 0.9
EUR A 3.1 2.2 1.7 0.9 3.0–7.0 2.0–6.0
EUR B 1.7 1.2 1.7 0.9 3.0–8.0 2.0–5.0
EUR C 2.0 1.5 " "
SEAR B 1.6 0.9 1.2 0.6
SEAR D 2.5 1.4 1.7 1.3 ,2.0 ,1.0
WPR A 2.9 2.0 1.9 1.0 2.0–4.0 2.0–3.0
WPR B 2.8# 1.5# 4.8# 4.5# .3.0# ,3.0#
GBD: Global Burden of Disease Study; A: very low child and adult mortality; B: low child and adult mortality; C: low child mortality and high adult mortality; D: high child
and adult mortality; E: high child mortality and very high adult mortality; AFR: Africa; AMR: Americas; EMR: Eastern Mediterranean; EUR: Europe; SEAR: South-East Asia;
WPR: Western Pacific. #: aged o15 yrs; ": included with EUR B.
TABLE 4 Estimates of yrs lived with disability (YLDs), yrs of life lost (YLLs) and disability-adjusted life yrs (DALYs) due to
chronic obstructive pulmonary disease by region, 2000
YLD?100000 males-1 YLD?100000 females-1 YLL?100000 males-1 YLL?100000 females-1 Total YLD
thousands
Total YLL
thousands
Total DALYs
thousands
AFR D 49.8 11.2 152.9 136.1 102 482 584
AFR E 47.1 11.5 167.5 131.9 99 505 603
AMR A 340.7 270.3 216.7 202.2 944 648 1592
AMR B 179.0 209.5 134.5 92.9 860 502 1362
AMR D 159.4 95.4 73.6 90.2 91 58 149
EMR B 283.6 57.4 60.2 44.1 244 73 317
EMR D 123.1 58.6 105.9 100.3 126 142 268
EUR A 265.0 298.9 198.6 104.7 1160 619 1779
EUR B 140.9 175.3 40.9 27.8 343 74 418
EUR C 197.2 265.6 390.4 132.3 574 622 1196
SEAR B 209.8 171.3 185.4 118.6 752 600 1351
SEAR D 123.3 123.0 397.3 353.7 1660 5073 6733
WPR A 113.5 92.5 77.9 34.1 154 83 237
WPR B 236.2 95.4 407.8 493.8 2524 6777 9628
Total 188.9 140.1 286.2 260.9 9954 16543 26497
A: very low child and adult mortality; B: low child and adult mortality; C: low child mortality and high adult mortality; D: high child and adult mortality; E: high child mortality
and very high adult mortality; AFR: Africa; AMR: Americas; EMR: Eastern Mediterranean; EUR: Europe; SEAR: South-East Asia; WPR: Western Pacific.
FUTURE COPD PROJECTIONS A.D. LOPEZ ET AL.
404 VOLUME 27 NUMBER 2 EUROPEAN RESPIRATORY JOURNAL
knowledge about expected future trends of a disease can be
useful for many reasons, including planning of public-health
initiatives and healthcare services. Two general approaches are
in use to project future incidence or mortality trends:
extrapolation based on previous trends and forecasts based
on multivariate risk factor models [1]. Both methods assume
some constancy of whatever they model on, either that the
relationship of risk factors with disease stays the same over
time or, in extrapolation, that past trends continue. This section
considers the use of these methods to project the future burden
of COPD, and subsequently illustrates some of the issues that
may arise in making projections, using a Bayesian extrapola-
tion method for mortality in England and Wales. While this
method is readily transferable to other countries, results may
differ as smoking prevalence has been declining for several
decades in the UK.
Risk factor methods
Arguably, the most well-known COPD projections come from
the authoritative and widely quoted GBD Study, which
projected that COPD would rise to the third leading cause of
death worldwide in 2020 [1]. These projections arose from a
risk factor model designed to guide international health policy.
The model was deliberately simple to facilitate its use across a
range of diseases and countries. Risk factors included in the
model were projected income, education and smoking levels,
and these were used to make projections for disease groupings
for 2020 by world region, for baseline, optimistic and
pessimistic scenarios [1]. The model provided a relatively
poor fit (r2 coefficients typically ,30% for most age and sex
groupings), i.e. only 30% of the variation in the model could be
explained by the risk factors included. Levels of specific
respiratory diseases such as COPD at the country level
were then inferred from that country’s current distribution of
specific conditions within respiratory disease. While the GBD
model has been greatly influential in directing attention at
respiratory disease internationally, other approaches are
arguably better at producing projections at a country level
where good risk factor and healthcare data exist.
One of the few risk factor models specific for COPD was
published by FEENSTRA et al. [39] in 2001. This used a system-
dynamic multistate lifetable model to make 20-yr predictions
about the COPD burden in the Netherlands. Main risk factors
for COPD were age and detailed smoking data (survey data
with age- and sex-specific starting and stopping smoking
rates). RRs for developing COPD related to these risk factors
were derived from cohort studies (chiefly from the USA).
These were then applied to COPD incidence and prevalence
data from a combination of general practice databases, national
mortality and population data, and to information on
healthcare usage and costs. This complex model provided
detailed information on projected prevalence, DALYs, mortal-
ity and costs. As well as providing detailed information,
informative sensitivity analyses can be conducted using risk
factor models. For example, the basic model suggested an
increase in COPD prevalence of 43% in males and 142% in
females between 1995 and 2015 [39]. However, if all smokers
quit in 1995 and nobody else started, COPD prevalence in 2015
was still projected to increase by around 40% in males and
129% in females, due to future ageing of the population and
the legacy of previous smoking. There are some disadvantages
of such models: 1) they are complex and can, therefore, be
difficult to implement; 2) the complexity magnifies the
possibility of combining errors and biases in the data; and 3)
such models are not readily transferable to countries lacking
comprehensive healthcare information.
Extrapolation methods
The alternative approach to risk factor models is to extrapolate
from past trends. Extrapolation models can be readily used at
the level of country and are often simpler to implement than
risk factor models, although they may be complex to interpret.
They are probably best suited to short-term projections because
past trends are likely to become less relevant further into
the future.
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FIGURE 4. Comparison of yrs lived with disability (YLD) per 1,000 for a) males
and b) females in Global Burden of Disease (GBD) Study 1990 (h) and GBD 2000
(&) estimates. This figure compares results for 2000, using subregions, with results
for 1990, where a different categorisation of subregions was used. EMR BD:
Eastern Mediterranean, combining low child and adult mortality, and high child and
adult mortality; AMR BD: Americas, combining the regions with low child and adult
mortality, and high child and adult mortality, which corresponds to the 1990
categorisation of Latin America and the Caribbean; AFR: Africa; SEAR B + WPR B:
this category comprises some of the South-East Asia region with low child and adult
mortality, and two-thirds of the Western Pacific region with low child and adult
mortality, which allows comparison with the 2000 estimates; SEAR D: South-East
Asia region with high child and adult mortality, which corresponds to India; EUR BC:
Europe, combining low child and adult mortality, and low child mortality and high
adult mortality; A: industrialised regions.
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Extrapolation methods are mainly used with mortality data.
This is because mortality data are readily available in many
countries over a sufficient time period (25–30 yrs are advis-
able), with reasonably stable definitions of disease and coding
over time and of acceptable quality. Simple extrapolations,
such as those from a logistic regression model of mortality
trends [40], are likely to give a misleading impression of future
COPD trends as they do not take into account factors such as
population age changes, year-to-year (period) influences such
as influenza epidemics, and generational (cohort) influences
such as lifetime smoking patterns that may all strongly
influence future COPD mortality [41, 42]. Age–period–cohort
models are more sophisticated extrapolation methods that take
into account all of these factors and have been most widely
used to make projections of cancer mortality [41–48].
Assessment of uncertainty in disease projections
Leaving aside the inherent problems of attempting to assess
the future at all, variations in projected figures relate to the
choice of model assumptions and also to statistical uncertainty
in the model. While most published projections examine the
impact of model assumptions through sensitivity analyses,
very few published analyses report uncertainty intervals
(confidence or credible intervals), although some authors refer
to ways in which these may be calculated [1, 41]. The omission
of uncertainty intervals may affect interpretation of the
projections. The rest of this section illustrates this point in a
demonstration of a recently developed Bayesian age–period–
cohort model to make short-term mortality projections for
COPD for England and Wales [49].
Methods
Data
COPD and population data for England and Wales 1945–1999
by 5-yr age band were obtained from the Office for National
Statistics (ONS) [50–54]. Codes used for COPD included those
for asthma, chronic bronchitis and emphysema due to
concerns about distinguishing between these conditions using
death certificate data [55]; asthma constituted ,7% of deaths
over this time period. Population projections for 2000–2009
onwards were obtained from the Government Actuarial Dept
(London, UK). As changes in ICD coding over time can lead to
artefactual changes in rates, age-specific conversion factors for
COPD mortality covering change years were obtained from the
ONS [56–60], except for the changes from the ICD8 to ICD9,
which are not available.
Statistical analyses
Projections of numbers of deaths were conducted using a
Bayesian age–period–cohort model implemented in a freeware
programme called Bayesian Age-period-cohort Modelling and
Prediction (BAMP) [49, 61]. Here, period effects represent
factors affecting people of all ages at a particular point in time
(e.g. treatment advances or influenza epidemics), while cohort
effects represent factors more common in people born at a
particular point in time (e.g. smoking habits).
Statistical model
The statistical method is described in more detail elsewhere
[49]. In brief, the underlying assumption on which the
statistical model is based is that observed mortality rates result
from a constant rate modified by age, period and cohort effects,
plus unobserved covariates. The model is implemented in a
Bayesian framework and is a development of work by
CLAYTON and SCHIFFLERS [62] and BERZUINI et al. [63].
Differing assumptions (prior beliefs or priors) about the
smoothness of the age, period and cohort parameters could
be incorporated into the model. The smoothing prior defined
as random walk (RW)1 favoured solution parameters with
constancy of first-order differences of age, period or cohort
parameters, thereby assuming a smoothness of age, period and
cohort trends, whereas the RW2 prior penalised deviations
from a linear trend of the second-order differences of age,
period or cohort parameters, assuming a smoothness of the
rate of change of parameters [49].
To select the best model with which to make projections,
predictions of numbers of deaths were made for the last 10 yrs
of existing data (1990–1999), where the actual numbers of
deaths were already known. Predictions were based on
analyses for 1950–1989 using RW1 or RW2 constraints and
data sets adjusted or unadjusted for ICD coding changes. The
combinations of data set and model that most closely predicted
the numbers of deaths for the last 10 yrs of existing data,
assessed by comparing the square root of the sum of median
predictive deviances, were then used to project mortality from
2000 to 2009.
Within the Bayesian framework, information from both prior
beliefs (priors) and the data are combined to give a posterior
distribution, from which actual values for parameters can be
derived though repeated iterative sampling. The first 2,000
samples representing ‘‘burn in’’ for the model were discarded,
and quoted results are based on a further 100,000 samples.
Median values and centiles specified at 5% and 95% and 25%
and 75% were obtained.
Results
Descriptive analyses
Deaths from COPD in males and younger females have
declined in England and Wales in recent years, with the decline
starting at different periods in different age groups, but have
been increasing in older females (fig. 5). The impact of coding
changes was minimal, as artefactual changes in rates across
change years were not visible. However, marked year-to-year
variations were also visible in these graphs, and these were
located as period effects in the age–period–cohort analyses.
Making predictions for existing data using age–period–cohort
analyses
Posterior median predictions from all models overestimated
the total number of deaths occurring in 1990–1999. In the best
models, overestimation was ,9% for males and 5% for females
(table 5). However, the actual numbers of deaths for each year
and age group generally lay within the 5% and 95% centiles of
the predictions. Using data adjusted for ICD changes gave
slightly worse predictions in females but slightly better
predictions in males (table 5).
Projections for 2000–2009 using age–period–cohort analyses
Median projections are presented together with 90% credible
intervals, which were obtained from the 5% and 95% centile
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estimates. The 90% credible intervals can be interpreted as
intervals where there is 90% confidence that the ‘‘true’’ value
lies within these bounds. Projections using the best models
suggested that COPD death rates in males aged o45 yrs
would continue the decline of recent decades, falling by 24%
(90% credible interval -52–14%) by 2009 from a 1999 baseline
(table 6). In females, projections suggested fluctuations in
COPD death rates and wide credible intervals, with 2% higher
rates in 2009 (90% credible interval -40–65%) than in 1999
(table 6). A fall in rates was strongly suggested for males aged
in their 60s and 70s and females in their 60s (the 95th centiles
for projected rates in 2009 were lower than in 1999), but, for
other age groups, 90% credible intervals encompassed both a
fall and rise in rates (fig. 6).
The corresponding posterior median projections of numbers of
deaths (data not shown) showed an ,10% fall in COPD male
deaths and a rise (with minor year-to-year fluctuations) in
female deaths of ,10% from a 1999 baseline to ,14,000 each
per yr in 2009. The median number of deaths for females at
14,410 (90% credible interval 8,184–21,886) were projected to
become higher than those for males at 14,259 (90% credible
interval 8,824–21,145) for the first time by 2008, but credible
intervals showed wide overlap. Despite higher numbers of
deaths, the posterior median rates in females were projected to
remain lower than males throughout the period (table 6) due
to demographic changes in the population.
Interpretation
To the current authors’ knowledge, this is the first use of a
Bayesian age–period–cohort method to make mortality projec-
tions for COPD. Median projections suggested that male
COPD death rates in the UK would continue the decline seen
in recent decades and fall by a quarter over the decade,
whereas those in females were projected to remain fairly static.
Perhaps the most striking feature of the projections was the
wide credible intervals. It should also be noted that intervals
quoted will underestimate the statistical uncertainty in the
model because uncertainties about the population projections
for 2000–2009 have not been incorporated. As previously
noted, credible or confidence intervals are rarely presented in
published projections.
The major factor responsible for the wide credible intervals for
COPD mortality was the marked year-to-year variations in
mortality rates (fig. 5) located as period effects. These period
effects probably relate to variations in activity of respiratory
infections, including respiratory syncytial virus and influenza.
Similar methods used to project lung cancer mortality, which
had much less year-to-year variation than COPD, resulted in
much narrower credible intervals [64]. Wide credible intervals
do not affect the median projections and are of interest in their
own right. For example, although COPD mortality rates in
males were likely to decrease overall, the results suggest that,
given the experience in previous years, there could be marked
year-to-year fluctuations in numbers of deaths. This informa-
tion might be of particular use when planning services.
Furthermore, the upper credible intervals could be interpreted
as suggesting that there is a 95% certainty that COPD mortality
rates in males in 2009 would only be 14% higher than in 1999,
even if respiratory infection activity were high, whereas, in
females, projections suggested they could be up to two-thirds
higher than in 1999 with 95% certainty. This type of
information would not have been available from the risk
factor models employed by FEENSTRA et al. [39] or the GBD
Study [1] as infectious disease activity was not included in the
model and confidence intervals were not presented.
Another issue relates to the degree of certainty required for the
projections. Many Bayesian studies use 70% or 80% credible
intervals (which are lower than the 95% confidence interval
levels used in frequentist analyses in recognition that certain
prior knowledge about the data, as well as statistical
uncertainty, are reflected in the results) and the 90% bounds
presented here may be more stringent than required for
planning purposes [65].
Accounting for changes in smoking
A refinement of age–period–cohort analyses is to substitute
one or more of the parameters by changes in a known risk
factor with an appropriate lag, e.g. the impact of changes in
average tar content in cigarettes on lung cancer mortality,
which might be expected to exert a period effect (change in
rates affecting all ages) [45]. This is less easy for COPD as,
unlike cancers, the components of cigarette smoke leading to
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FIGURE 5. Chronic obstructive pulmonary disease mortality during the period
of 1945–1999 in a) males and b) females aged o45 yrs in England and Wales (UK),
unadjusted for International Classification of Disease (ICD) coding version changes
(----: ICD change years). .: aged 45–54 yrs; m: aged 55–64 yrs; &: aged 65–
74 yrs; ¤: aged 75–84 yrs; $: aged o85 yrs.
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disease development have not been definitively characterised
[66]. Repeating the analyses presented here using annual
tobacco consumption by sex lagged 20 or 40 yrs, as the period
effect did not improve predictions and resulted in an
unrealistic widening of credible intervals, particularly in
females [67]. This seemingly unintuitive result can be
explained using the knowledge that, in the UK, there are
known strong year of birth (cohort) effects in smoking
behaviour with males first taking up smoking in large numbers
around the time of the First World War and females doing so
in the 1940s. The current authors’ interpretation is that
cumulative smoking exposure is the most important predictor
of COPD mortality trends, and this is already captured by the
cohort effect. Therefore, any impact of year-to-year changes in
smoking habits, which would be reflected in the period effect,
adds little explanatory information to the model [42, 56].
Another possible explanation is that the measure used was too
crude an indicator of tobacco use. Substituting the cohort
parameter with a suitable smoking covariate is unlikely to
improve predictions over a short time period because the data
will hold very good information about cohort trends for the
oldest cohorts with the largest numbers of deaths. Cohort
smoking information may be able to improve predictions in
younger cohorts in the short term, but these constitute the
smallest number of deaths [41]. It could potentially improve
predictions over a longer time period, assuming smoking
remains a major influence on COPD mortality.
Data
Mortality data in the UK are of high quality, represent almost
100% of deaths and are usually certified by a medical
practitioner or coroner [68]. Changes in diagnostic patterns
TABLE 5 Comparison of predictions with actual total number of chronic obstructive pulmonary disease (COPD) plus asthma
deaths for 1990–1999 in England and Wales in those aged o45 yrs
Smoothing
constraint
Data bridge-coded
adjusted?
% difference of sum of
posterior median
predictions from actual
total number of deaths
% of age-group categories
where actual numbers
lie within 25–75% centiles
of predictions#
% of age-group categories
where actual numbers lie
within 5–95% centiles of
predictions#
Square root of sum of
posterior median
predictive deviances
COPD males
RW1 No +10.8 62.2 93.3 36.39
RW1 Yes +9.0 57.8 94.4 35.10
RW2 No +76.9 91.1 100.0 217.77
RW2 Yes +50.0 91.1 100.0 194.21
COPD females
RW1 No +4.9 80.0 93.3 34.96
RW1 Yes +5.6 80.0 93.3 36.01
RW2 No +72.6 96.7 100 238.55
RW2 Yes +69.7 96.7 100 244.52
RW: random walk smoothing constraint. #: represents 90 cells, nine age-group categories over 10 yrs.
TABLE 6 Projected posterior chronic obstructive pulmonary disease (COPD) mortality rates per 100,000 population and numbers
of COPD deaths for 2000–2009 in England and Wales, for those aged o45 yrs and actual rates/numbers for 1999
Year# COPD mortality rates Numbers of COPD deaths
Males median (90% CI) Females median (95% CI) Males median (95% CI) Females median (90% CI)
1999 165.1 113.0 15583 12438
2000 164.5 (143.4–187.9) 119.8 (98.3–146.8) 15847 (13814–18095) 13269 (10885–16260)
2001 160.7 (129.0–193.2) 120.1 (94.9–154.7) 15655 (12567–18820) 13395 (10586–17253)
2002 156.5 (122.6–197.1) 121.9 (90.6–161.1) 15427 (12081–19430) 13678 (10174–18080)
2003 152.3 (112.3–200.0) 119.8 (80.7–178.9) 15204 (11213–19967) 13547 (9130–20231)
2004 147.1 (103.3–198.2) 118.3 (77.7–179.9) 14886 (10458–20060) 13498 (8864–20524)
2005 142.2 (99.7–200.8) 119.4 (76.0–186.0 14607 (10246–20636) 13750 (8744–21406)
2006 138.1 (93.0–195.2) 117.8 (71.7–187.4) 14429 (9718–20390) 13706 (8347–21802)
2007 134.6 (86.8–189.9) 121.2 (74.2–188.1) 14315 (9227–20193) 14267 (8732–22148)
2008 131.7 (81.5–195.2) 120.8 (68.6–183.5) 14259 (8824–21145) 14410 (8184–21886)
2009 126.3 (79.3–188.7) 115.7 (67.7–186.6) 13944 (8758–20832) 13985 (8184–22559)
CI: credible interval. #: the data for 1999 are actual rates/numbers, and the remaining years are projected.
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are inevitable over a 50-yr period, but the present authors
consider that data were compatible over this time period. Both
COPD and lung cancer have distinctive clinical and
radiographic features, and the ICD codes used to define
COPD were deliberately broad to allow for changes in
diagnosis over time. The analysis was restricted to those aged
o45 yrs as most of the deaths from obstructive lung disease
occur in older individuals. Including younger age groups
would have been possible, but this would have reduced
precision and widened credible intervals [69]. There was no
advantage to using data adjusted with factors derived from
bridge-coding exercises in this analysis because changes to
numbers of deaths resulting from coding revisions were small.
A separate issue concerns the usefulness of mortality as an
estimate of the public health burden of obstructive lung
disease. Some advantages are that mortality and population
data are readily available in many countries, information on
the quality of the data is available, and this type of analysis is
relatively cheap and straightforward. However, it is likely to
underestimate the burden of disease. This analysis used
COPD statistics relating to underlying cause of death on the
death certificate, but, in England and Wales, this only
accounts for ,60% of individuals with the disease mentioned
anywhere on the death certificate [70]. The Tucson cohort
study suggested that only 33% of patients with COPD in life
had COPD listed anywhere on the death certificate, although
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FIGURE 6. Modelled and actual chronic obstructive pulmonary disease
mortality rates per 1,000 for males (a–i) and females (j–r) in England and Wales for
1945–1999 and projected rates for 2000–2009 (----: cut-off line) for the following
age groups: 45–49 yrs (a, j); 50–54 yrs (b, k); 55–59 yrs (c, l); 60–64 yrs (d, m); 65–
69 yrs (e, n); 70–74 yrs (f, o); 75–79 yrs (g, p); 80–84 yrs (h, q); 85–89 yrs (i–r).
Lines represent 5%, 25%, 50%, 75% and 95% centiles of modelled rates. Actual
rates are represented by X.
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this percentage increased to 77% in subjects with moderate-to-
severe disease [71].
In conclusion, predicting future trends in a disease is difficult.
Both risk factor and age–period–cohort approaches are based
on a number of assumptions; for example, that the dose–
response coefficient of the risk factor will remain constant into
the future or that current age, period and cohort trends will
continue. The extent to which projection methods can predict
existing data should be readily available for published
projections. As all methods have flaws, a more complete
assessment can be made by comparing projections obtained
using risk factor and extrapolation methods.
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